Hosts panel discussion on ‘Application of AI technology in treatment of Chronic Diseases’
Indian Institute of Technology Madras Research Park (IITMRP) today released the findings of the Evaluation Report of Twin Health’s treatment program for reversing Chronic metabolic disease including Type 2 Diabetes. The technology evaluation report will help assess the effectiveness of treatment methodology, which aims to reverse chronic metabolic diseases, particularly Type 2 Diabetes, empowering patients with a medication free recovery.
As part of the report launch, IITMRP also hosted a panel discussion on ‘Application of AI technology in treatment of Chronic Diseases’ where panelists shared perspectives from industry, academia and the insurance sector. Prof. Mohanasankar Sivaprakasam (Vice President, IIITMRP), Padma Shri Dr. Shashank R. Joshi (Consultant Endocrine & Metabolic Physician, Lilavati Hospital), Dr. S Prakash (Chairperson – Health Committee of General Insurance Council, Advisory Committee, Member of NABH, Co-Founder and Formerly MD of Star Health Insurance), Prof. Gaurav Raina (IIT Madras) and Mr. Raghavendran J (Associate Director, Leading Data Science and Digital Analytics, Novartis) were part of the panel discussion, moderated by Dr. Maluk Mohamed (Co-Founder, Global Vice President (Research) & Head) – Twin India.
In India, insulin resistance and metabolic syndrome are widely prevalent. Studies have reported that in urban Indian population, the prevalence in particular age groups were found to be overall 25%. (Approximately 31% in women and 18.5% in men). Moreover an individual with diabetes often spends upto 19 lakhs on medication alone over a lifetime.
Twin Health, an AI health technology R&D company at IITMRP, aims to solve this issue using their advanced patented ‘Whole Body Digital Twin™’ technology to help heal dysfunctional metabolism — the root cause of many chronic diseases.
Prof. Ashok Jhunjhunwala, President, IIT Madras Research Park, Prof. Mohanasankar Sivaprakasam and Prof. Gaurav Raina initiated an evaluation report. IITMRP assessed the effectiveness of this twin treatment methodology that aims to reverse chronic metabolic diseases, particularly Type 2 Diabetes, empowering patients with a medication free recovery.
A comprehensive analysis of health parameters, recovery rates, medication usage and food transformation were initiated with 206 patients following Twin Precision Treatment (intervention group) and 82 Patients following usual Care (control group), through a Randomized Control Trial.
Key Findings from the Evaluation Report:
- Over 90% of Twin Precision Treatment patients achieved normal blood sugar and stopped taking all Diabetes medications, including insulin, within 3 months.
- After one year, 73% of the intervention group patients achieved Type 2 Diabetes remission, compared to none in the control group.
- Over 50% reduction in the risk of experiencing a cardiovascular event in prime patients
- Over 50% of Twin Precision Treatment patients achieved normal Systolic and Diastolic Blood Pressure levels within 3 months.
- Transformation from red/orange food to green food over a 1-year period found to be effective for patients who showed engagement and adherence to the Twin Program
Remarking on the treatment methodology, Prof. Ashok Jhunjhunwala, President, IITM Research Park said, “Twin Health is a unique company at IITM Research Park. It promises reversal of diabetes, (reversal rather than control) and it does it without any medicines. It is somewhat like nature control. It helps telling you whether the food you ate today helps or hurts your sugar level. It advises that you temporarily stop taking red food which is hurting your body, just take the green food which helps your body. Overtime the body will heal and one by one the red food will become green.”
Dr. Maluk Mohamed, Co-Founder, Global Vice President (Research) & Head – Twin India said, “Proud to be a part of the IITMRP ecosystem, the birthplace of the groundbreaking digital twin technology. This innovation marks a significant stride in precision medicine, offering new hope for individuals battling chronic conditions such as diabetes, obesity, fatty liver, and PCOS. Traditionally viewed as lifelong and progressively worsening diseases, these conditions are now being effectively reversed, thanks to this technology.”
“This first-of-its-kind solution, driven by advanced AI and machine learning, not only alleviates the physical burden of metabolic diseases but also significantly reduces the financial strain associated with their chronic nature. By harnessing the power of this technology, we are opening doors to a future where chronic metabolic diseases are no longer lifelong afflictions but manageable conditions with the potential for reversal. This represents a paradigm shift in the treatment and perception of these widespread health challenges.”, he added.
The Twin precision treatment has benefited 21,274 members since the start of commercial operations in India. Out of the enrolled members, 93% have experienced improved health outcomes, with 67% achieving diabetes reversal. The RCT results have also been peer reviewed and published by prestigious healthcare organisations including the American Diabetes Association and over 40+ reputed medical journals and global conferences.
Find the links to the featured publications below: